KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Debt (2019 - 2025)

Rigel Pharmaceuticals has reported Total Debt over the past 7 years, most recently at $82.1 million for Q4 2025.

  • Quarterly results put Total Debt at $82.1 million for Q4 2025, up 37.58% from a year ago — trailing twelve months through Dec 2025 was $82.1 million (up 37.58% YoY), and the annual figure for FY2025 was $82.1 million, up 37.58%.
  • Total Debt for Q4 2025 was $82.1 million at Rigel Pharmaceuticals, up from $59.7 million in the prior quarter.
  • Over the last five years, Total Debt for RIGL hit a ceiling of $82.1 million in Q4 2025 and a floor of $19.8 million in Q1 2021.
  • Median Total Debt over the past 5 years was $59.6 million (2023), compared with a mean of $47.8 million.
  • Biggest five-year swings in Total Debt: skyrocketed 101.89% in 2021 and later decreased 0.05% in 2025.
  • Rigel Pharmaceuticals' Total Debt stood at $19.9 million in 2021, then soared by 98.09% to $39.4 million in 2022, then surged by 51.09% to $59.6 million in 2023, then rose by 0.13% to $59.7 million in 2024, then soared by 37.58% to $82.1 million in 2025.
  • The last three reported values for Total Debt were $82.1 million (Q4 2025), $59.7 million (Q3 2025), and $59.8 million (Q2 2025) per Business Quant data.